Bassil Dahiyat, Ph.D., president and CEO of Xencor, a publicly traded biotech he founded right out of graduate school, shares three formative experiences gained as a first-time entrepreneur.
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
Mark Rothera spent the majority of his career working for U.S.-based biopharmas. So, when he had the opportunity to work in his home country and preferred therapeutic area, he pursued it relentlessly.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
Rachel King, CEO and cofounder of GlycoMimetics, talks about women in the biopharma industry as part of this preview of her feature story that appears in the May issue of LSL.
Richard Pops, CEO of Alkermes, discusses his philosophy of being forward looking, but shares how such an approach can also have its drawbacks.
Deborah Waterhouse, CEO of ViiV Healthcare, provides insight as to how GSK’s joint venture has been able to achieve and maintain success.
Deborah Waterhouse, CEO of GSK’s joint venture ViiV Healthcare, discusses her three keys to business success.
Intellia Therapeutics CEO, John Leonard, M.D., shares a formative leadership experience from his days at Abbott Laboratories.
Intellia Therapeutics CEO, John Leonard, M.D., provides insight into why he entered industry, and his drive to be an entrepreneur.
|
|
|
|
|
|
|
|
|